Navigation Links
Nanomix Initiates Clinical Testing of Point of Care IVD Cardiac Panel
Date:2/11/2013

EMERYVILLE, Calif., Feb. 11, 2013 /PRNewswire/ -- Nanomix Inc., (Nanomix), a leading nanotechnology company focused on development of next generation point of care diagnostic tests to enable earlier and more accurate testing in hospital and pre-hospital settings, announced today that it has initiated clinical testing in the U.S. to evaluate the Omega-3 Cardiac Panel.  The panel quantitatively tests whole blood specimens for levels of cardiac troponin I (cTnI), myoglobin and H-FABP, biomarkers often used as an aid in the diagnosis of myocardial infarction (MI). The initial testing will be conducted with approximately 170 normally healthy subjects and will provide baseline performance information that will form the basis of future registration clinical studies. 

Chest pain is the second leading cause of admittance to Emergency Departments in the US.  An early and accurate diagnosis of chest pain complaints is key to achieving improved patient outcomes through earlier treatment intervention.  The Omega-3 handheld system is designed for use in the Emergency Department and by pre-hospital First Responders in the field to speed the diagnosis of an MI. The combination of a handheld electronic reader and wholly contained cartridge allow the cardiac test panel to be performed at the point of patient contact, avoiding delays associated with transporting samples to laboratory for traditional testing.   Using a whole blood sample, the Omega-3 handheld system is designed to produce results in approximately 10 minutes at the site of first patient interaction, potentially reducing diagnosis of an MI by as much as an hour.  The cardiac test panel is the first developed for the Nanomix platform and extensions into other emergency medicine and infectious disease areas are planned to follow. 

About Nanomix Inc.

Nanomix's leadership in carbon nanotubes and nanoscale electronic sensors has enabled the development of the next generation of Point of Care testing systems where superior performance and rapid results can both be achieved in virtually any setting.  Omega-3, the Nanomix mobile diagnostic platform, is designed to perform multiple in-vitro diagnostic assays simultaneously from a single whole-blood sample.  The compact size of the electronic and credit card sized disposable test cartridge can be configured to run a wide variety of tests from range of patient samples.

For more information, visit: http://www.nano.com

Contact:

David Ludvigson
dludvigson@nano.com
Nanomix, Inc.
5980 Horton St, Suite 600
Emeryville, CA  94608
Phone:  1-510-428-5332


'/>"/>
SOURCE Nanomix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ADVENTRX Initiates Pivotal Phase 3 Study of ANX-188
2. uniQure Initiates Phase I in Acute Intermittent Porphyria
3. Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies
4. The Acute Liver Failure Study Group Initiates Phase 2a Study of OCR-002 for Treatment of Acute Liver Failure after Acetaminophen Overdose
5. Isis Pharmaceuticals Initiates Phase 1b/2a Study Of ISIS-SMNRx In Patients With Spinal Muscular Atrophy
6. Isis Initiates Phase 2 Study Of ISIS-FXIRX In Patients Undergoing Knee Replacement Surgery
7. Synthetic Biologics Initiates Development of Monoclonal Antibodies for Treatment of Acinetobacter Infections
8. Healthpoint Biotherapeutics Initiates Phase III Study of Unique Investigational Cell-Based Therapy for Venous Leg Ulcers
9. New Jersey Health Foundation Initiates Program To Spur Innovative Research
10. Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
11. ImmusanT Initiates Clinical Trials of Nexvax2 Therapeutic Vaccine for Celiac Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., a ... drug prescribing process, today announced it closed $25 million in ... venture capital firm based in Seattle ... Venture Partners . The Series B round included participation from ... in 2014, and GV (formerly Google Ventures). As ...
(Date:4/20/2017)... 2017 Research and Markets has announced ... Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive ... offering. ... market was valued at US$ 7,167.6 Mn in 2015, and ... at a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... ... Getting enough sleep affects much more than energy – it also has mental and physical ... compromise motor reaction time, which can increase the risk of having a car accident. ... from the NSF to help you sleep better and feel better:, , ...
(Date:4/28/2017)... ... ... The Radiology Business Management Association (RBMA) is pleased to announce its ... has been in place since the RBMA was founded in 1968 with all board ... Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive officer for Clinical ...
(Date:4/28/2017)... ... April 28, 2017 , ... From April ... of Urgent Care Medicine will host industry leaders for the annual spring Convention ... those in the industry adapt to the issues currently affecting urgent care and ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... which name the Creator responds to and which He does not. Yisrayl says with ... which one is the true name, but he says with a little Scripture, backed with ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation Limited, a ... its Nova Skin Sciences division, recently announced the launch of Allumière Antiaging Cream, ... power of an anti-aging concentrate. , Anogeissus Leiocarpa Bark Extract and ...
Breaking Medicine News(10 mins):